Svmuu News Nasdaq-listed company NovaBay Pharmaceuticals has been renamed Stablecoin Development Corporation (stock ticker changed from NBY to SDEV), shifting its business focus to the cryptocurrency and stablecoin-related sectors.
The company previously completed a private placement of approximately $134 million and allocated the majority of the funds to increase its holdings of SKY, the governance token of the decentralized stablecoin protocol Sky. It currently holds approximately 2.06 billion SKY tokens, representing about 8.78% of the total supply, with a corresponding market value of approximately $147 million. A portion of these tokens was purchased on the secondary market at an average price of around $0.065.
Furthermore, the company has begun staking its SKY holdings to earn rewards, having accumulated approximately 26.6 million SKY tokens as staking rewards to date. (CoinDesk)
SDEV Invests Over $100 Million to Increase Holdings of SKY Tokens, Holding Approximately 8.78% of Supply
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
9
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
10
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
Markets Today
Recommended Reading








